Clinical TrialApr 17, 2026, 05:17 PM
iBio to Begin Phase 1 Clinical Trial of IBIO-600 in Australia
AI Summary
iBio, Inc. announced it received Clinical Trial Notification acknowledgement and ethics approval to initiate a first-in-human Phase 1 clinical trial for IBIO-600 in Australia. The company expects to dose the first participants in the second quarter of 2026. Additionally, iBio filed an amendment to correct a typographical error, confirming Series G warrants will expire on May 20, 2026, and updated outstanding warrant and common stock figures.
Key Highlights
- Received approval for IBIO-600 Phase 1 clinical trial in Australia.
- First participants expected to be dosed in Q2 2026.
- Series G warrants expiration date corrected to May 20, 2026.
- Original Series G warrants for up to 35,770,000 shares.
Price Impact
More from IBIO